As Shanghai enters a second week of a city-wide lockdown with no signs of policy easing, officials are promoting the use of traditional Chinese medicines rather than Pfizer's recently approved Paxlovid.

Torrent expects US FDA’s final approval for Allergan/Almirall’s Aczone, a dapsone formulation for acne vulgaris, in February, even as it awaits regulatory clearance for manufacturing sites. Meanwhile, it has launched molnupiravir in India and is hiking its domestic sales force by 400-500.

Domestic companies have won most of the bids in China's latest government procurement round for 62 drugs, marking an end to the previous dominance of off-patent products from multinationals.

A lack of new launches and price erosion caused a sharp dip in Torrent’s Q3 US revenues, but the company plans to ramp up its presence in Brazil and Germany to build momentum. Meanwhile, the field force in India has been downsized with an aim to defocus on older brands.